The study of the competitive environment and development trends of drug manufacturers based on the system of market indicators
Social Pharmacy in Health Care · 03.07.2026 · 12 (2) · 52-60
DOI: 10.24959/sphhcj.26.397 ↗Kurz gefasst
Fachartikel in der Zeitschrift Social Pharmacy in Health Care, online erschienen am 03.07.2026. Verfasst von I. O. Surikova und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The current competitive environment of the pharmaceutical industry is characterized by a high level of turbulence, which requires business entities to move from rigid strategic planning to the adaptive management paradigm.
Aim
To study the geospatial concentration and assess the development trends of industrial pharmaceutical enterprises in a volatile macroeconomic environment. Materials and methods. The empirical base of the study was the analytical data from “Proxima Research” regarding the activities of 745 drug manufacturers in the pharmaceutical market of Ukraine. Methods of system, statistical, geospatial analysis, and qualimetric modeling were applied. The market positioning was assessed using the system of integral indicators, such as the innovation index, evolution index, inflation index, and elasticity of demand index. Statistical processing and data visualization were performed in MS Excel and using Google Gemini artificial intelligence tools. Results and discussion. A high level of territorial concentration of domestic production has been determined (74 companies hold more than 28% of the market in value terms). At the same time, the aggressive market expansion of importing companies has been revealed; their evolutionary growth rates outpace domestic capacities. Matrix modeling has proven the existence of a direct correlation between the proactive innovation policy and stable leading growth of the enterprise. The analysis of pricing strategies has confirmed the absolute inelasticity of the basic demand, which actualizes the problem of social responsibility of drug manufacturers. Based on the results of the qualimetric assessment, it has been found that 86.4% of manufacturers have a critically low level of innovation.
Conclusions
It has been proven that in conditions of turbulence, inertial development trends lead to a loss of market positions. The survival of a pharmaceutical enterprise and the preservation of the resilience of the national healthcare system are possible exclusively through the implementation of adaptive management models, which core is the continuous innovation activity and socially responsible pricing policy.
Zitieren
APA
Surikova, I. O., & Chernyavsky, A. V. (2026). The study of the competitive environment and development trends of drug manufacturers based on the system of market indicators. Social Pharmacy in Health Care, 12(2), 52-60. https://doi.org/10.24959/sphhcj.26.397
Vancouver
Surikova IO, Chernyavsky AV. The study of the competitive environment and development trends of drug manufacturers based on the system of market indicators. Social Pharmacy in Health Care. 2026;12(2):52-60. doi:10.24959/sphhcj.26.397
BibTeX
@article{Surikova2026,
author = {Surikova, I. O. and Chernyavsky, A. V.},
title = {The study of the competitive environment and development trends of drug manufacturers based on the system of market indicators},
journal = {Social Pharmacy in Health Care},
year = {2026},
volume = {12},
number = {2},
pages = {52--60},
doi = {10.24959/sphhcj.26.397}
}
EUVIMED